Ikarian Capital’s Enliven Therapeutics ELVN Stock Holding History

Ikarian Capital’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.28M	Buy	+83,700	New	+$2.32M	0.27%	79

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ikarian Capital's ELVN Position: Q2 2025 in Review

Ikarian Capital sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 289,538 shares — an estimated $5.7M sold.

Ikarian Capital first reported a position in ELVN in Q2 2024 and held it in 4 quarters. The position peaked at $13.7M in Q2 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

Ikarian Capital reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 289,538 Enliven Therapeutics shares in Q2 2025, an estimated $5.7M.
Ikarian Capital first reported a position in Enliven Therapeutics in Q2 2024 and held it in 4 quarters.
Ikarian Capital's Enliven Therapeutics position peaked at $13.7M in Q2 2024.
124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.